How does BFBIO's PE Ratio compare to its peers?

BFBIO is expensive based on its Price-To-Earnings Ratio (46.5x) compared to the peer average (19.2x).

How does BFBIO's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?

BFBIO is expensive based on its Price-To-Earnings Ratio (46.5x) compared to the Asian Pharmaceuticals industry average (24.3x).

What is BFBIO's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate BFBIO's Price-To-Earnings Fair Ratio for valuation analysis.

What is the Fair Price of BFBIO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate BFBIO's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is lower than the current share price.

BFBIO Stock Overview

A diversified biotech pharmaceutical company, manufactures, imports, and sells pharmaceutical products. More details

BFBIO fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	5/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 33.5% per year

Earnings grew by 79% over the past year

Risk Analysis

Highly volatile share price over the past 3 months compared to the PK market

Does not have a meaningful market cap (PKR19B)

My Notes

Capture your thoughts, links and company narrative

BF Biosciences Limited Competitors

Ferozsons Laboratories

KASE:FEROZ

PK₨14.1b

Citi Pharma

KASE:CPHL

PK₨15.3b

Hoechst Pakistan

KASE:HPL

PK₨26.3b

AGP

KASE:AGP

PK₨45.8b

Price History & Performance

Summary of share price highs, lows and changes for BF Biosciences
Historical stock prices
Current Share Price	PK₨210.39
52 Week High	PK₨251.50
52 Week Low	PK₨76.06
Beta	0
1 Month Change	40.05%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	150.88%

Recent updates

Shareholder Returns

	BFBIO	PK Pharmaceuticals	PK Market
7D	-2.9%	-5.4%	-4.6%
1Y	n/a	160.1%	54.3%

Return vs Industry: Insufficient data to determine how BFBIO performed against the PK Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how BFBIO performed against the PK Market.

Price Volatility

Is BFBIO's price volatile compared to industry and market?
BFBIO volatility
BFBIO Average Weekly Movement	12.7%
Pharmaceuticals Industry Average Movement	7.1%
Market Average Movement	7.1%
10% most volatile stocks in PK Market	10.1%
10% least volatile stocks in PK Market	4.8%

Stable Share Price: BFBIO's share price has been volatile over the past 3 months compared to the PK market.

Volatility Over Time: Insufficient data to determine BFBIO's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2006	n/a	Akhter Waheed	www.bfbio.com

BF Biosciences Limited, a diversified biotech pharmaceutical company, manufactures, imports, and sells pharmaceutical products. It offers a range of products in the areas of nephrology, cardiology, gastroenterology, diabetes, oncology, anti-viral, and hepatology. The company was incorporated in 2006 and is headquartered in Raiwind, Pakistan.

BF Biosciences Limited Fundamentals Summary

How do BF Biosciences's earnings and revenue compare to its market cap?
BFBIO fundamental statistics
Market cap	PK₨18.58b
Earnings (TTM)	PK₨399.91m
Revenue (TTM)	PK₨4.08b

46.5x

P/E Ratio

4.6x

P/S Ratio

Is BFBIO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BFBIO income statement (TTM)
Revenue	PK₨4.08b
Cost of Revenue	PK₨2.36b
Gross Profit	PK₨1.72b
Other Expenses	PK₨1.32b
Earnings	PK₨399.91m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	4.53
Gross Margin	42.06%
Net Profit Margin	9.80%
Debt/Equity Ratio	91.2%

How did BFBIO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/21 21:43
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BF Biosciences Limited is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Azeem Akhundzada	Sherman Securities (Pvt.) Limited

BF Biosciences KASE:BFBIO Stock Report